BioCentury
ARTICLE | Company News

Amplimmune, GlaxoSmithKline deal

August 9, 2010 7:00 AM UTC

Amplimmune granted GlaxoSmithKline an exclusive, worldwide license to develop and commercialize AMP-224 and other next-generation fusion proteins targeting PD-1 receptor ( PDCD1; PD-1; CD279). Ampl...